Načítá se...
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
BACKGROUND: Manipulation of immune checkpoints such as CTLA4 or PD-1 with targeted antibodies has recently emerged as an effective anticancer strategy in multiple malignancies. Sarcomas are a heterogeneous group of diseases in need of more effective treatments. Different subtypes of soft tissue and...
Uloženo v:
| Vydáno v: | Clin Sarcoma Res |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5200964/ https://ncbi.nlm.nih.gov/pubmed/28042471 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13569-016-0064-0 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|